Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma — Asher Chanan‐Khan (2012) | RDL Network
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma
Asher Chanan‐Khan, Donna Weber, Meletios A Dimopoulos, Christine Chen, Reuben Niesvizky, Michael Wang, Andrew R. Belch, Michel Attal, Andrew Spencer, Miles Prince, Marta Olesnyckyj, Jerome B. Zeldis, Zhinuan Yu, Robert Knight
David S. Siegel, Paul G. Richardson, Meletios A Dimopoulos, Philippe Moreau, C Mitsiades, D. Weber, Jennifer Houp, Christine K. Gause, Scott Vuocolo, Joe Eid, Thorsten Graef, Kenneth C. Anderson
David S. Siegel, Paul G. Richardson, Meletios A Dimopoulos, P Moreau, C Mitsiades, Diane Weber, Jennifer Houp, Christine K. Gause, Scott Vuocolo, Joe Eid, Thorsten Graef, KS Anderson
David S. Siegel, Meletios A Dimopoulos, Heinz Ludwig, Thierry Façon, Hartmut Goldschmidt, Andrzej Jakubowiak, Jesús F. San Miguel, Mihaela Obreja, Julie Blædel, A. Keith Stewart
Antonio Palumbo, Meletios A Dimopoulos, Jesús F. San Miguel, Jean‐Luc Harousseau, Michel Attal, Mohamad A. Hussein, Stefan Knop, Heinz Ludwig, Marie von Lilienfeld‐Toal, Pieter Sonneveld
Discussion(0)
No comments yet. Be the first to comment.